Dermavant acquisition expands Organon’s dermatology portfolio
Pharmaceutical Technology
OCTOBER 29, 2024
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology portfolio.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
OCTOBER 29, 2024
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, to expand its dermatology portfolio.
Pharmaceutical Technology
FEBRUARY 1, 2024
Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 18, 2024
Organon has agreed a $1.2bn deal to buy dermatology specialist Dermavant and its psoriasis therapy Vtama, under FDA review for atopic dermatitis
Pharmaceutical Technology
NOVEMBER 15, 2023
Almirall has entered into a collaboration with Absci for the development and commercialisation of new treatments for dermatological ailments.
pharmaphorum
FEBRUARY 12, 2024
Medicxi has combined six biotechs with dermatology medicines in development in a single drugmaker, called Alys Pharma, which starts life with $100 million in financing.
pharmaphorum
FEBRUARY 1, 2024
Almirall has formed a three-year alliance with Microsoft designed to accelerate the discovery and development of personalised dermatology therapies.
BioPharma Reporter
DECEMBER 14, 2023
UK-based Lindus Health and US-based Thirty Madison today (December 14) announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.
Fierce Pharma
DECEMBER 15, 2023
About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.
Bio Pharma Dive
SEPTEMBER 18, 2024
The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.
pharmaphorum
AUGUST 23, 2023
Leo builds dermatology pipeline with Timber deal Phil.Taylor Wed, 23/08/2023 - 08:40 Bookmark this
Pharmaceutical Technology
SEPTEMBER 19, 2024
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
Bio Pharma Dive
JULY 19, 2022
The cream, known as Opzelura, is now the only treatment approved in the U.S. to repigment skin in patients with the most common form of vitiligo.
pharmaphorum
AUGUST 11, 2023
Strong solutions for increasing dermatology research diversity: Trust me, I’ve got skin in the game Mike.Hammerton Fri, 11/08/2023 - 08:00 Bookmark this
Pharma Mirror
APRIL 8, 2022
BARCELONA, Spain and Dundee, UK, a global biopharmaceutical company focused on skin health, today announced a research collaboration with the University of Dundee, a top-ranked university in the UK in biological sciences, to develop a novel approach against chronic and debilitating dermatology diseases where itch, or pruritus, plays a dominant role.
Fierce Pharma
AUGUST 13, 2024
Itching for leadership in 'therapeutic dermatology,' Galderma wins FDA nod for Nemluvio to treat prurigo nodularis kdunleavy Tue, 08/13/2024 - 10:38
Medical Xpress
JANUARY 24, 2023
A dermatology program first developed by the University of Missouri in 2015 can bring life-saving diagnoses of skin conditions to communities without adequate dermatologic care.
Pharmaceutical Technology
JULY 22, 2024
Shares in the company opened 3.9% higher buoyed by an H1 performance in line with expectations.
pharmaphorum
NOVEMBER 11, 2021
KNUTSFORD, United Kingdom — Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology. Kenneth B Gordon, MD, Professor and Chair of Dermatology at the Medical College of Wisconsin. November 10, 2021, UK.
WCG Clinical
OCTOBER 9, 2023
The dermatology market is embarking on tremendous growth and sponsors need to be ready. Over the last 12 months, dermatology-focused studies have increased by roughly 20%, with top focus areas including psoriasis, atopic dermatitis, and alopecia. This rapid growth brings new challenges. Efficiency and speed are critical.
Pharmaceutical Technology
MAY 17, 2024
J&J has gained access to several bispecific antibody programmes, including the Phase I-ready asset PX128 for atopic dermatitis and asthma.
Bio Pharma Dive
OCTOBER 4, 2022
The acquisition, Incyte’s first of an entire company, hands the pharmaceutical company a potentially long lasting treatment for the skin disease vitiligo.
BioPharma Reporter
AUGUST 22, 2023
LEO Pharma has acquired Timber Pharmaceuticals, in a deal that will add an âattractiveâ late stage asset to its pipeline in medical dermatology, the company said.
WCG Clinical
SEPTEMBER 20, 2023
Welcome to the recorded session of ‘Optimizing Endpoint Assessments for Dermatology Studies.’ In this insightful webinar, we take a deep dive into dermatology trials and discuss how standardizing rater qualification and training can solve common challenges and protect the quality and integrity of endpoint data.
BioPharma Reporter
FEBRUARY 13, 2024
Alys Pharmaceuticals, an immuno-dermatology focused company, has launched with $100 million financing by Medicxi and an R&D pipeline enabled by multiple platform technologies.
pharmaphorum
OCTOBER 9, 2023
Champion Innovation at the 7th Dermatology Drug Development Summit Mike.Hammerton Mon, 09/10/2023 - 14:39 Bookmark this
pharmaphorum
MAY 9, 2023
4th Dermatology Drug Development Summit Europe Mike.Hammerton Tue, 05/09/2023 - 20:11 Bookmark this
Outsourcing Pharma
MAY 23, 2022
With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.
Pharmaceutical Technology
OCTOBER 25, 2023
The funds will go towards Phase II trials for the company’s two candidates treating seborrheic keratoses and melasma.
BioTech 365
OCTOBER 22, 2021
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021 Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021 The Company also highlights the study … Continue reading →
pharmaphorum
OCTOBER 2, 2024
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
Fierce Pharma
SEPTEMBER 18, 2024
With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 with a potential blockbuster in tow. billion, the companies announced Wednesday.
Pharmaceutical Technology
AUGUST 22, 2024
Leo Pharma spent $36m to acquire Timber Pharmaceuticals last year, along with its lead dermatology asset TMB-001.
Fierce Pharma
NOVEMBER 4, 2024
Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. |
XTalks
JUNE 2, 2021
In this episode, Ayesha talks about Google’s new AI-based dermatology tool designed to help people identify and research conditions of the skin, hair and nails. Read the full articles here: Google Launches AI-Based Dermatology Assist Tool. WHO Calls for Probe into SARS-CoV-2 Origins as Lab Leak Theories Intensify.
BioTech 365
JULY 8, 2021
Melanoma Research Alliance Announces 13 Dermatology Fellowship Award Recipients Melanoma Research Alliance Announces 13 Dermatology Fellowship Award Recipients Initiative Represents MRAs Largest Investment in Prevention and Early Detection WASHINGTON–(BUSINESS WIRE)–The Melanoma Research Alliance, the largest non-profit funder of melanoma (..)
Pharmaceutical Technology
MAY 28, 2024
J&J has made its second dermatology deal this month, adding Numab’s bispecific antibody NM26 to its growing atopic dermatitis drug portfolio.
Pharmaceutical Technology
MARCH 14, 2024
Almirall has signed a licence agreement to gain the rights for Eloxx Pharmaceuticals’ ZKN-013 for rare dermatological disease indications.
WCG Clinical
MARCH 30, 2023
Uniform Live Action Training Using InvestigatorSpace Speeds Up Study Start Times In one case, a global pharmaceutical company used WCG’s training solutions to support two dermatology studies they were running.
Fierce Pharma
OCTOBER 9, 2024
Amid a transformation effort under CEO Christophe Bourdon, Danish dermatology expert Leo Pharma is embarking on another round of layoffs and relocations. | Leo is closing and relocating up to 250 roles as part of the “next step” in the dermatology company’s evolving strategy, a company spokesperson told Fierce Pharma.
BioTech 365
JANUARY 14, 2022
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference DURHAM, N.C., 14, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the the Company” or “Novan”) … Continue reading →
BioTech 365
MAY 10, 2021
DermTech Presents Mini-Symposia at 2021 Society of Investigational Dermatology Virtual Summit DermTech Presents Mini-Symposia at 2021 Society of Investigational Dermatology Virtual Summit LA JOLLA, Calif.–(BUSINESS –(BUSINESS WIRE)–DermTech, Inc.
BioTech 365
DECEMBER 29, 2021
Ellen Turner’s Dermatology Office Celebrates Launch of Audrose Beauty Collection with Vogue100 Dr. Ellen Turner’s Dermatology Office Celebrates Launch of Audrose Beauty Collection with Vogue100 The Dallas-based Skin Care Team Joined Audrose™ Founder Justine Nichole for an Exclusive December … Continue reading →
BioTech 365
JANUARY 19, 2021
DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021 DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021 LA JOLLA, Calif.–(BUSINESS NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin … Continue reading →
Pharma Times
APRIL 12, 2023
The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content